{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T04:07:27Z","timestamp":1765512447011,"version":"3.48.0"},"reference-count":56,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":23,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Health Science Reports"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Acute myeloid leukemia (AML) is the most common acute leukemia, which is associated with high morbidity and mortality, and its incidence rate is increasing. Despite tremendous advancements in AML treatment, managing the condition is still challenging. Receptor kinase inhibitors like sorafenib have recently raised concerns about monotherapy, and combination treatments are now being investigated as a potential therapeutic avenue. To classify medications taken in conjunction with sorafenib and analyze their combined effects, we reviewed the prior research findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A thorough literature search utilizing several databases, including PubMed, Google Scholar, Scopus, Embase, and Cochrane, yielded 78 relevant articles until October 2023. Search terms including AML, combination, and Sorafenib were utilized during the database search to find relevant papers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Complete remission (CR) in the combination of sorafenib with \u201ccytarabine and idarubicin\u201d, \u201cVorinostat and Bortezomib, Clofarabine\u201d, \u201cFludarabine and Busulfan\u201d, \u201c5\u2010azacytidine\u201d and \u201cQuizartinib, Midostaurin and Giltertinib\u201d respectively \u201c99% and 94%\u201d, \u201c27% and 3%\u201d, 66.6%, \u201c45%, 26%, 16%\u201d, \u201c71% and 52%\u201d. Furthermore, the overall survival (OS) values for the combination of sorafenib with \u201cQuizartinib, Midostaurin, and Giltertinib\u201d, \u201ccytarabine, daunorubicin\u201d and \u201c5\u2010azacitidine\u201d were \u201c80%\u201d \u201c62% 45%\u201d, and 24%, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Accordingly, several studies suggest that sorafenib's anticancer effectiveness may be enhanced with chemotherapy drugs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/hsr2.71412","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T07:25:14Z","timestamp":1761290714000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Combination Therapy With Sorafenib in Therapeutic Strategy of Acute Myeloid Leukemia. Is It Promising? A Narrative Review"],"prefix":"10.1002","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0990-1230","authenticated-orcid":false,"given":"Mobina Nakhaei","family":"Shamahmood","sequence":"first","affiliation":[{"name":"Student Research Committee Birjand University of Medical Sciences Birjand Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abolfazl","family":"Miri","sequence":"additional","affiliation":[{"name":"Student Research Committee Zahedan University of Medical Sciences Zahedan Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4309-0582","authenticated-orcid":false,"given":"Fatemeh","family":"Mezginejad","sequence":"additional","affiliation":[{"name":"Department of Hematology, School of Allied Medicine, Cellular and Molecular Research Center Birjand University of Medical Sciences Birjand Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2015.0070"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-282632"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2014.08.001"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1247870"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00425-3"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.10"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.1820"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.4065\/81.2.247"},{"issue":"23","key":"e_1_2_10_10_1","first-page":"2508","article-title":"Sorafenib in Advanced Hepatocellular Carcinoma","volume":"359","author":"Llovet J. M.","year":"2008","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1503"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0033583508004745"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(04)00215-6"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10692"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404508"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.2174\/092986712803341548"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr107"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.54"},{"volume-title":"Essential Medical Statistics","year":"2010","author":"Kirkwood B. R.","key":"e_1_2_10_19_1"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781118715598.ch25"},{"volume-title":"Cytarabine","year":"2025","author":"Faruqi A.","key":"e_1_2_10_21_1"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199142040-00010"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-199500092-00003"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2461-5"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25553"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.4888"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-10-246470"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-09-3724"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-172007"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V120.21.1516.1516"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V112.11.768.768"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2016003053"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020301"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5154.160511"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V116.21.3272.3272"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.976.976"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2018.12.011"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1724"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199753060-00007"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1177\/106002809402800911"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.08.003"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-152450"},{"key":"e_1_2_10_43_1","first-page":"625","article-title":"Microbiological Production of 5\u2010Azacytidine. II. Isolation and Chemical Structure","volume":"6","author":"Bergy M. E.","year":"1966","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-54490-3_19"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2015.04.050"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25198"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1590\/s1679-45082017rc3784"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-12-19"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-222034"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620717721459"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0675-4"},{"issue":"1","key":"e_1_2_10_52_1","first-page":"104","article-title":"Gilteritinib: A Novel FLT3 Inhibitor for Relapsed\/Refractory Acute Myeloid Leukemia","volume":"11","author":"Marjoncu D.","year":"2020","journal-title":"Journal of the Advanced Practitioner in Oncology"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01994-x"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1913145"},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32387"},{"key":"e_1_2_10_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00677-7"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.14927"}],"container-title":["Health Science Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hsr2.71412","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T04:03:55Z","timestamp":1765512235000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hsr2.71412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":56,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1002\/hsr2.71412"],"URL":"https:\/\/doi.org\/10.1002\/hsr2.71412","archive":["Portico"],"relation":{},"ISSN":["2398-8835","2398-8835"],"issn-type":[{"type":"print","value":"2398-8835"},{"type":"electronic","value":"2398-8835"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"2024-11-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e71412"}}